NCT05973487View on ClinicalTrials.gov

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

840

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Head and Neck CancerCervical CancerNon-small Cell CarcinomaMelanomaOvarian CancerAnogenital CancersHPV - Anogenital Human Papilloma Virus InfectionHPV-Related Cervical CarcinomaHPV-Related CarcinomaHPV-Related Squamous Cell CarcinomaHPV-Related MalignancyHPV-Related AdenocarcinomaHPV Positive Oropharyngeal Squamous Cell CarcinomaHPV-Related Adenosquamous CarcinomaHPV-Associated Vaginal AdenocarcinomaHPV-Related Endocervical AdenocarcinomaHPV-Related Anal Squamous Cell CarcinomaHPV-Related Verrucous CarcinomaHPV-Related Penile Squamous Cell CarcinomaHPV-Related Vulvar Squamous Cell CarcinomaHPV Positive Rectal Squamous Cell Carcinoma
Interventions
BIOLOGICAL

TSC-204-A0201

Escalating doses of TSC-204-A0201 as a monotherapy

BIOLOGICAL

TSC-204-C0702

Escalating doses of TSC-204-C0702 as a monotherapy

BIOLOGICAL

TSC-200-A0201

Escalating doses of TSC-200-A0201 as a monotherapy

BIOLOGICAL

TSC-204-A0201 + TSC-204-C0702

Escalating doses of TSC-204-A0201 in combination with TSC-204-C0702

BIOLOGICAL

TSC-204-A0201 + TSC-200-A0201

Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201

BIOLOGICAL

TSC-204-C0702 + TSC-200-A0201

Escalating doses of TSC-204-C0702 in combination with TSC-200-A0201

BIOLOGICAL

TSC-204-A0201 + TSC-203-A0201

Escalating doses of TSC-204-A0201 in combination with TSC-203-A0201

BIOLOGICAL

TSC-204-C0702 + TSC-203-A0201

Escalating doses of TSC-204-C0702 in combination with TSC-203-A0201

BIOLOGICAL

TSC-200-A0201 + TSC-203-A0201

Escalating doses of TSC-200-A0201 in combination with TSC-203-A0201

BIOLOGICAL

TSC-203-A0201

Escalating doses of TSC-203-A0201 as a monotherapy

BIOLOGICAL

TSC-204-A0101

Escalating doses of TSC-204-A0101 as a monotherapy

BIOLOGICAL

TSC-201-B0702

Escalating doses of TSC-201-B0702 as a monotherapy

BIOLOGICAL

TSC-204-A0201 + TSC-204-A0101

Escalating doses of TSC-204-A0201 in combination with TSC-204-A0101

BIOLOGICAL

TSC-204-A0201 + TSC-201-B0702

Escalating doses of TSC-204-A0201 in combination with TSC-201-B0702

BIOLOGICAL

TSC-204-C0702 + TSC-204-A0101

Escalating doses of TSC-204-C0702 in combination with TSC-204-A0101

BIOLOGICAL

TSC-204-C0702 + TSC-201-B0702

Escalating doses of TSC-204-C0702 in combination with TSC-201-B0702

BIOLOGICAL

TSC-200-A0201 + TSC-204-A0101

Escalating doses of TSC-200-A0201 in combination with TSC-204-A0101

BIOLOGICAL

TSC-200-A0201 + TSC-201-B0702

Escalating doses of TSC-200-A0201 in combination with TSC-201-B0702

BIOLOGICAL

TSC-203-A0201 + TSC-204-A0101

Escalating doses of TSC-203-A0201 in combination with TSC-204-A0101

BIOLOGICAL

TSC-203-A0201 + TSC-201-B0702

Escalating doses of TSC-203-A0201 in combination with TSC-201-B0702

BIOLOGICAL

TSC-202-A0201

Escalating doses of TSC-202-A0201 as a monotherapy

BIOLOGICAL

TSC-204-A0201 + TSC-202-A0201

Escalating doses of TSC-204-A0201 in combination with TSC-202-A0201

BIOLOGICAL

TSC-204-C0702 + TSC-202-A0201

Escalating doses of TSC-204-C0702 in combination with TSC-202-A0201

BIOLOGICAL

TSC-200-A0201 + TSC-202-A0201

Escalating doses of TSC-200-A0201 in combination with TSC-202-A0201

BIOLOGICAL

TSC-203-A0201 + TSC-202-A0201

Escalating doses of TSC-203-A0201 in combination with TSC-202-A0201

BIOLOGICAL

TSC-204-A0101 + TSC-202-A0201

Escalating doses of TSC-204-A0101 in combination with TSC-202-A0201

BIOLOGICAL

TSC-201-B0702 + TSC-202-A0201

Escalating doses of TSC-201-B0702 in combination with TSC-202-A0201

Trial Locations (21)

10032

RECRUITING

Columbia University Herbert Irving Comprehensive Cancer Center, New York

15224

RECRUITING

Allegheny Hospitals Network, Pittsburgh

15232

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

32806

RECRUITING

Orlando Health, Orlando

33021

RECRUITING

Memorial Healthcare System, Hollywood

33136

RECRUITING

University of Miami, Sylvester Comprehensive Cancer Center, Miami

33606

RECRUITING

University of South Florida, Tampa

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

40202

RECRUITING

Norton Cancer Institute, Louisville

44195

RECRUITING

The Cleveland Clinic, Cleveland

45242

RECRUITING

Oncology Hematology Care, Cincinnati

48201

RECRUITING

Karmanos Cancer Institute, Detroit

55455

RECRUITING

University of Minnesota Masonic Cancer Center, Minneapolis

60637

RECRUITING

University of Chicago, Chicago

73104

RECRUITING

OU Health Stephenson Cancer Center, Oklahoma City

77030

RECRUITING

Baylor College of Medicine, Houston

85258

RECRUITING

HonorHealth Research and Innovation Institute, Scottsdale

92037

RECRUITING

University of California San Diego, San Diego

97213

RECRUITING

Providence Cancer Institute Franz Clinic, Portland

06510

RECRUITING

Yale Cancer Center, New Haven

All Listed Sponsors
lead

TScan Therapeutics, Inc.

INDUSTRY